From the Journals

SABCS Highlights: Advances in Oral SERD's for Breast Cancer

Harold Burstein, MD, PhD, and Rinath M. Jeselsohn, MD, discuss the lidERA, evERA, and EMBER-3 trials researching oral selective estrogen receptor degraders (SERDs).

  • March 17, 2026

Share

The lidERA, evERA, and EMBER-3 trials represent significant advances in the research of oral selective estrogen receptor degraders (SERDs), as discussed by Harold Burstein, MD, PhD, and Rinath M. Jeselsohn, MD. These trials aim to evaluate the effectiveness and safety of SERDs in treating hormone receptor-positive breast cancer. Such therapies have the potential to improve patient outcomes by targeting resistant cancer cells and offering new avenues for treatment, particularly for patients with advanced disease.

Original Source(s)

SABCS Highlights: Advances in Oral SERD's for Breast Cancer

  • March 17, 2026

Related Content

2025 San Antonio Breast Cancer Symposium Recap

Harold Burstein, MD, PhD, summarizes important breakthroughs presented at the 2025 San Antonio Breast Cancer Symposium.

  • March 17, 2026

SABCS 2025 Highlights: Patient Perspective

Lindsay Northrop, breast cancer survivor and patient advocate at Dana-Farber, talks with Harold Burstein, MD, PhD, about how recent advances in breast cancer research presented at the 2025 San Antonio Breast Cancer Symposium will impact patient care.

  • March 17, 2026

SABCS 2025 Highlights: Hormone Replacement Therapy for Breast Cancer

Harold Burstein, MD, PhD, and Wendy Y. Chen, MD, MPH, discuss research in hormone replacement therapy for breast cancer that was presented at the 2025 San Antonio Breast Cancer Symposium.

  • March 17, 2026